Clinical Trials Directory

Trials / Completed

CompletedNCT02152696

Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location

Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location - a Randomized Clinical Trial of Women at Risk for an Ectopic Pregnancy: Active Treatment Versus No Treatment

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
255 (actual)
Sponsor
Yale University · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a randomized controlled trial to compare three currently available management strategies for women with a persisting pregnancy of unknown location (PPUL), which makes them at-risk for ectopic pregnancy. We will recruit hemodynamically stable women with a confirmed PPUL to be randomized to one of three strategies: 1) Uterine evacuation followed by methotrexate (MTX) for some (those that have evidence of a non visualized ectopic pregnancy) 2) Empiric treatment with MTX for all 3) Expectant management. Randomization will be 1:1:1 into these three arms. After randomization, they will be followed and treated clinically as is indicated by the progression of their condition. Primary outcome measures: uneventful decline of hCG to 5 IU/mL.

Conditions

Interventions

TypeNameDescription
DRUGMethotrexateTwo Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
PROCEDUREUterine EvacuationUterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
OTHERExpectant ManagementPregnancy will be expectantly managed using serum hcg monitoring

Timeline

Start date
2014-07-25
Primary completion
2019-08-01
Completion
2019-08-19
First posted
2014-06-02
Last updated
2020-12-08
Results posted
2020-10-26

Locations

17 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02152696. Inclusion in this directory is not an endorsement.